OXFORD, England, October 1, 2013 /PRNewswire/ --
GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced that it has won two major awards in the 2013 BIG (Business Intelligence Group) Awards for Business.
BIG has selected GlySure as Small Business of the Year and it also won New Product of the Year for its CBGM technology.
Business Intelligence Group's BIG Awards specialize in recognizing top performing companies and organizations. The organization's proprietary and unique scoring system selectively measures performance across multiple business domains, and rewards companies whose achievements stand above those of their peers.
"Glysure's mission and product to help control glucose levels in real time is clearly in demand," said Dawn Fordyce of the Business Intelligence Group. "With so much at stake, Glysure's continuous blood glucose monitoring system will surely save countless lives and healthcare costs."
Over two years of human use trials in over 150 intensive care unit (ICU) patients have proven that GlySure's CBGM technology can be used to continuously measure glucose levels with an extremely high degree of accuracy and repeatability across three-to-five days of a patient's stay, which is key to improving outcomes and reducing costs in the ICU. GlySure recently commenced a multi-center CE Trial on cardiac surgery patients, which the company expects to complete this fall.
"It is a great honor to be recognized by the Business Intelligence Group," said GlySure CEO Chris Jones. "This industry recognition validates the tremendous momentum we've achieved to date in delivering on the promise of Tight Glycemic Control."
GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com
Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870. email@example.com
Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127. firstname.lastname@example.org